Skip to main content

Hindson Benjamin J.'s Form 4 filing

10x Genomics, Inc. (TXG) · filed Oct 5, 2021

Accession no.
0001567619-21-017948
Filed
Oct 5, 2021
Trade date
Oct 1, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.98M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hindson Benjamin J.CIK 0001786391Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 1, 2021Class A Common StockMOption exerciseAcquired+41,666$5.04+$209,996.6488,783Direct
Oct 1, 2021Class A Common StockSSaleDisposed−4,400$142.16F2−$625,50484,383Direct
Oct 1, 2021Class A Common StockSSaleDisposed−13,297$143.13F3−$1,903,199.6171,086Direct
Oct 1, 2021Class A Common StockSSaleDisposed−21,469$143.97F4−$3,090,891.9349,617Direct
Oct 1, 2021Class A Common StockSSaleDisposed−2,500$144.77F5−$361,92547,117Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 1, 2021Class A Common StockMOption exerciseDisposed−41,666$0.00$061,116Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $141.53 to $142.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $142.53 to $143.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $143.53 to $144.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $144.54 to $145.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Scientific Officer and President

Read the full filing on SEC EDGAR (opens in a new tab)